Effects of exercise vs bisphosphonates on bone mineral density in breast cancer patients receiving chemotherapy

Journal of Supportive Oncology

Volumn 7, Issue 3, 2009, Pages 101-107

  Swenson, Karen K ^a   Nissen M J , Mary Jo ^a   Anderson, Elsie ^a   Shapiro, Alice ^a   Schouboe, John ^a   Leach, Joseph ^a  

^a PARK NICOLLET INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; CALCIUM CARBONATE; CYCLOPHOSPHAMIDE; DOXORUBICIN; TAMOXIFEN; VITAMIN D; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE;

ADULT; ARTICLE; BODY COMPOSITION; BONE DENSITY; BONE DISEASE; BONE TURNOVER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; HUMAN; KINESIOTHERAPY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OSTEOLYSIS; OSTEOPENIA; PATIENT COMPLIANCE; PHYSICAL ACTIVITY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; VERTEBRA FRACTURE; BREAST TUMOR; CALCIUM INTAKE; DRUG EFFECT; EXERCISE; INTRAVENOUS DRUG ADMINISTRATION; METABOLIC BONE DISEASE; MIDDLE AGED; PHOTON ABSORPTIOMETRY; PHYSIOLOGY; TREATMENT OUTCOME;

ABSORPTIOMETRY, PHOTON; ADULT; ANTINEOPLASTIC AGENTS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; BREAST NEOPLASMS; CALCIUM, DIETARY; DIPHOSPHONATES; EXERCISE; FEMALE; HUMANS; IMIDAZOLES; INJECTIONS, INTRAVENOUS; MIDDLE AGED; QUALITY OF LIFE; TREATMENT OUTCOME; VITAMIN D;

EID: 68249134241     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA J Cancer Clin 2008;58:71-96.
2. Ries LAG, Melbert D, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2004, National Cancer Institute. Bethesda, MD, www.seer.cancer.gov/csr/1975_2004/, based on November 2006 SEER data submission, posted to the SEER Web site, 2007. Accessed April 23, 2009.
3. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996;14:1718-1729.
4. Twiss JJ, Waltman N, Ott CD, Gross GJ, Lindsey AM, Moore TE. Bone mineral density in postmenopausal breast cancer survivors. J Am Acad Nurse Pract 2001;13:276-284.
5. Chen Z, Maricic M, Pettinger M, et al. Osteoporosis and rate of bone loss among post-menopausal survivors of breast cancer. Cancer 2005;104:1520-1530.
6. Kanis JA, McCloskey EV, Powles T, Paterson AH, Ashley S, Spector T. A high incidence of vertebral fracture in women with breast cancer. Br J Cancer 1999;79:1179-1181.
7. Brufsky A, Harker WG, Beck JT, et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 2007;25:829-836.
8. Bundred NJ, Campbell ID, Davidson N, et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST study results. Cancer 2008;112:1001-1010.
9. Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2007;25:820-828.
10. Schwartz AL, Winters-Stone K, Gallucci B. Exercise effects on bone mineral density in women with breast cancer receiving adjuvant chemotherapy. Oncol Nurs Forum 2007;34:627-633.
11. Courneya KS, Friedenreich CM. Physical exercise and quality of life following cancer diagnosis: a literature review. Ann Behav Med 1999;21:171-179.
12. Courneya KS, Mackey JR, Bell GJ, Jones LW, Field CJ, Fairey AS. Randomized controlled trial of exercise training in postmenopausal breast cancer survivors: cardiopulmonary and quality of life outcomes. J Clin Oncol 2003;21:1660-1668.
13. Mock V, Pickett M, Ropka ME, et al. Fatigue and quality of life outcomes of exercise during cancer treatment. Cancer Pract 2001;9:119-127.
14. Schwartz AL. Daily fatigue patterns and effect of exercise in women with breast cancer. Cancer Pract 2000;8:16-24.
15. Segal R, Evans W, Johnson D, et al. Structured exercise improves physical functioning in women with stages I and II breast cancer: results of a randomized clinical trial. J Clin Oncol 2001;19:657-665.
16. Iwane M, Arita M, Tomimoto S, et al. Walking 10,000 steps/day or more reduces blood pressure and sympathetic nerve activity in mild essential hypertension. Hypertens Res 2000;23:573-580.
17. Miller WR, Rollnick S. Motivational Interviewing: Preparing People for Change. 2nd ed. New York, NY: The Guilford Press; 2002.
18. Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002;346:653-661.
19. Marcus R. Role of exercise in preventing and treating osteoporosis. Rheum Dis Clin North Am 2001;27:131-141.
20. Paffenbarger RS Jr, Blair SN, Lee IM, Hyde RT. Measurement of physical activity to assess health effects in free-living populations. Med Sci Sports Exerc 1993;25:60-70.
21. Cauley JA, LaPorte RE, Sandler RB, Schramm MM, Kriska AM. Comparison of methods to measure physical activity in postmenopausal women. Am J Clin Nutr 1987;45:14-22.
22. Schwartz AL. The Schwartz Cancer Fatigue Scale: testing reliability and validity. Oncol Nurs Forum 1998;25:711-717.
23. Schwartz AL. Fatigue mediates the effects of exercise on quality of life. Qual Life Res 1999;8:529-538.
24. Cleeland CS, Mendoza TR, Wang XS, et al. Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer 2000;89:1634-1646.
25. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. conceptual framework and item selection. Med Care 1992;30:473-483.
26. Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 2001;19:3306-3311.
27. Eastell R, Adams JE, Coleman RE, et al. Effect of anastrozole on bone mineral density: 5-year results from the Anastrozole, Tamoxifen, Alone or in Combination trial 18233230. J Clin Oncol 2008;26:1051-1057.
28. Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996;14:78-84.
29. Hershman DL, McMahon DJ, Crew KD, et al. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol 2008;26:4739-4745.